Press Releases

November 18, 2024
Cancer Targeted Technology Receives Fast Track $2.4M Grant to Develop an Innovative PSMA-Targeted Small Molecule Drug Conjugate for Prostate Cancer

June 29, 2021
Cancer Targeted Technology Receives Milestone Payment for Development of Diagnostic PET Imaging Agent for Prostate Cancer

November 6, 2018
Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer

October 23, 2018
Cancer Targeted Technology Receives an SBIR Grant and Announces Expansion of Its Pipeline

February 12, 2018
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer

April 18, 2017
CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences

April 12, 2017
Cancer Targeted Technology Announces Advances with its PSMA-targeted PET Imaging and Radiotherapeutic Agents for Prostate Cancer at Upcoming Conferences

December 19, 2016
Cancer Targeted Technology Commences Second Phase of a $2.3M Contract to Develop an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer

December 12, 2016
Cancer Targeted Technology Commences Phase I Clinical Trial of CTT1057, a Diagnostic Imaging Agent for Prostate Cancer

May 5, 2015
Cancer Targeted Technology Receives $2 Million Small Business Innovation (SBIR) Grant to Advance its PET Imaging Diagnostic to Clinical Trials in Prostate Cancer

December 14, 2010
Cancer Targeted Technology Enters into a Research and License Option Agreement with Bayer Pharma AG to Advance a Cancer PET Imaging Agent toward Clinical Trials

April 16, 2010
Beatrice Langton-Webster, CEO of Cancer Targeted Technology interviewed by Mr. Bob Crimmons